

Resource Summary Report

Generated by ASWG on Aug 10, 2026

Anti-Human CD49D (Integrin alpha 4) (Natalizumab) - Dylight® 488

RRID:AB_2893892

Type: Antibody

Proper Citation

Leinco Technologies Cat# LT1111, RRID:AB_2893892

Antibody Information

URL: http://antibodyregistry.org/AB_2893892

Proper Citation: Leinco Technologies Cat# LT1111, RRID:AB_2893892

Target Antigen: CD49D

Host Organism: human

Clonality: recombinant monoclonal

Comments: Applications: FC

Info: This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Natalizumab. Natalizumab binds to the alpha 4 subunit of $\alpha 4\beta 1$ and $\alpha 4\beta 7$ integrins. This product is for research use only.

Antibody Name: Anti-Human CD49D (Integrin alpha 4) (Natalizumab) - Dylight® 488

Description: This recombinant monoclonal targets CD49D

Target Organism: human

Clone ID: clone: Hu114

Antibody ID: AB_2893892

Vendor: Leinco Technologies

Catalog Number: LT1111

Record Creation Time: 20250820T001926+0000

Record Last Update: 20250820T075823+0000

Ratings and Alerts

No rating or validation information has been found for Anti-Human CD49D (Integrin alpha 4) (Natalizumab) - Dylight® 488.

No alerts have been found for Anti-Human CD49D (Integrin alpha 4) (Natalizumab) - Dylight® 488.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We have not found any literature mentions for this resource.